48 results Stibbe advises Aedifica Stibbe advises Aedifica, a Belgian listed company investing in health care real estate, on its acquisition of four senior housing sites in The Netherlands. Stibbe represents Mylan On 27 July 2015, Teva Pharmaceutical Industries announced that it has withdrawn its previously announced hostile bid to acquire Mylan N.V. Stibbe represented Mylan in this successful takeover defence and advised Mylan on both litigation and EU competition Stibbe advises Tornier Stibbe advises Tornier N.V. on its merger with Wright Medical Group, Inc. in an all stock transaction with a combined equity value of approximately $3.3 billion. Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business. Stibbe advises leading pharmaceutical company Stibbe assisted a leading pharmaceutical company in identifying the most cost-effective way to obtain in Belgium an improved pricing and reimbursement for new fixed-dose combination products composed of off-patent ingredients. Stibbe advises Canon Advising Canon in connection with their dispute with the State of the Netherlands on the procurement of framework contracts. Case won up to and including the Supreme Court. Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products. Stibbe advises SleepScore Labs Stibbe advised SleepScore Labs on the acquisition of Sleep.ai, a Netherlands-based digital health company. Stibbe advises Lundbeck Stibbe advised Lundbeck on the acquisition of Prexton Therapeutics BV for an amount of up to EUR 905 million. Stibbe advises Canon Medical Systems Stibbe advised Canon Medical Systems on the acquisition of Dutch medical equipment manufacturer Fysicon. Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of a care residence to be constructed in Bosch en Duin (municipality of Zeist). Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding. Pagination Previous page Page 1 Page 2 Current page 3
Stibbe advises Aedifica Stibbe advises Aedifica, a Belgian listed company investing in health care real estate, on its acquisition of four senior housing sites in The Netherlands.
Stibbe represents Mylan On 27 July 2015, Teva Pharmaceutical Industries announced that it has withdrawn its previously announced hostile bid to acquire Mylan N.V. Stibbe represented Mylan in this successful takeover defence and advised Mylan on both litigation and EU competition
Stibbe advises Tornier Stibbe advises Tornier N.V. on its merger with Wright Medical Group, Inc. in an all stock transaction with a combined equity value of approximately $3.3 billion.
Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.
Stibbe advises leading pharmaceutical company Stibbe assisted a leading pharmaceutical company in identifying the most cost-effective way to obtain in Belgium an improved pricing and reimbursement for new fixed-dose combination products composed of off-patent ingredients.
Stibbe advises Canon Advising Canon in connection with their dispute with the State of the Netherlands on the procurement of framework contracts. Case won up to and including the Supreme Court.
Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products.
Stibbe advises SleepScore Labs Stibbe advised SleepScore Labs on the acquisition of Sleep.ai, a Netherlands-based digital health company.
Stibbe advises Lundbeck Stibbe advised Lundbeck on the acquisition of Prexton Therapeutics BV for an amount of up to EUR 905 million.
Stibbe advises Canon Medical Systems Stibbe advised Canon Medical Systems on the acquisition of Dutch medical equipment manufacturer Fysicon.
Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of a care residence to be constructed in Bosch en Duin (municipality of Zeist).
Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding.